Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Cancer ; 104(6): 968-70, 2011 Mar 15.
Article in English | MEDLINE | ID: mdl-21326241

ABSTRACT

BACKGROUND: It has recently been reported by several sources that original (i.e., present in vivo) glioma cell phenotypes or genotypes cannot be maintained in vitro. For example, glioblastoma cell lines presenting EGFR amplification cannot be established. METHODS AND RESULTS: IDH1 sequencing and loss of heterozygosity analysis was performed for 15 surgery samples of astrocytoma and early and late passages of cells derived from those and for 11 archival samples. We were not able to culture tumour cells presenting IDH1 mutations originating from currently proceeded 10 tumours; the same results were observed in 7 samples of archival material. CONCLUSION: The IDH1 mutation is expected to be almost mutually exclusive with EGFR amplification, so glioma cells with IDH1 mutations seem to represent a new group of tumour cells, which cannot be readily analysed in vitro because of their elimination. The reasons for this intriguing phenomenon should be investigated since its understanding can help to define a new therapeutic approach based on simulating in vivo conditions, responsible for tumour cells elimination in vitro. Moreover, a new model for culturing glioma cells in vitro should be designed since the current one does not provide conditions corresponding to in vivo growth.


Subject(s)
Brain Neoplasms/genetics , Cell Proliferation , Glioma/genetics , Isocitrate Dehydrogenase/genetics , Biopsy , Brain Neoplasms/pathology , Cell Culture Techniques/standards , DNA Mutational Analysis , Freezing , Genes, erbB-1 , Glioma/pathology , Humans , Loss of Heterozygosity , Mutation/physiology , Tissue Preservation/methods , Tumor Cells, Cultured
2.
Cancer Genet Cytogenet ; 183(1): 14-20, 2008 May.
Article in English | MEDLINE | ID: mdl-18474292

ABSTRACT

Neurofibromin 2 (NF2), located on chromosome arm 22q, has been established as a tumor suppressor gene involved in meningioma pathogenesis. In our study, we investigated 149 meningiomas to determine whether there are additional tumor suppressor genes localized on chromosome 22q, apart from NF2, that might be involved in meningioma pathogenesis. The LOH analysis on chromosome 22q identified two regions of deletion: the first one, which is limited to the NF2 gene locus, and the second one, which is outside this location. The new minimal deletion region (MDR) included the following genes: BCR (breakpoint cluster region), RAB36 (a member of RAS oncogene family), GNAZ [guanine nucleotide binding protein (G protein), alpha-z polypeptide], and RTDR1 (rhabdoid tumor deletion region gene 1). The expression levels of all these genes, including NF2, were subsequently analyzed by quantitative real-time polymerase chain reaction. We observed a significantly lowered expression level of NF2 in meningiomas with 22q loss of heterozygosity (LOH) within NF2 region compared to the one in meningiomas with 22q retention of heterozygosity (ROH, P<0.05). Similarly, BCR showed a significantly lowered expression in meningiomas with 22q LOH within the new MDR compared to cases with 22q ROH (P<0.05). Our data, together with the already published information considering BCR function suggest that BCR can be considered as a candidate tumor suppressor gene localized on chromosome 22q which may be involved in meningioma pathogenesis.


Subject(s)
Chromosome Deletion , Chromosomes, Human, Pair 22 , Loss of Heterozygosity , Meningeal Neoplasms/genetics , Meningioma/genetics , Proto-Oncogene Proteins c-bcr/genetics , Adult , Aged , Aged, 80 and over , Down-Regulation , Female , Gene Expression Regulation, Neoplastic , Genes, Tumor Suppressor , Humans , Male , Meningeal Neoplasms/pathology , Meningioma/pathology , Middle Aged , Neoplasm Staging , Polymerase Chain Reaction/methods
3.
Br J Cancer ; 98(8): 1431-3, 2008 Apr 22.
Article in English | MEDLINE | ID: mdl-18349850

ABSTRACT

We screened 50 glioblastomas for P53 mutations. Five glioblastomas showed heterozygous mutations, while three were putatively heterozygous. Six of these eight glioblastomas showed elimination of wild-type P53 mRNA. These results strongly suggest that some sort of mechanism(s) favouring mutated over wild-type P53 mRNA exists in glioblastoma cells with heterozygous mutations of this gene.


Subject(s)
Brain Neoplasms/genetics , Genes, p53 , Glioblastoma/genetics , Mutation , RNA, Messenger/analysis , Tumor Suppressor Protein p53/genetics , Adolescent , Adult , Aged , Female , Humans , Loss of Heterozygosity , Male , Middle Aged , Promoter Regions, Genetic
4.
Clin Neuropathol ; 25(1): 18-24, 2006.
Article in English | MEDLINE | ID: mdl-16465770

ABSTRACT

BACKGROUND: Loss of heterozygosity (LOH) on 1p and 19q is observed in most oligodendroglial tumors. LOH on 10q appears to be less common in these tumors as compared to other gliomas. PATIENTS AND METHODS: We reviewed 14 patients with oligodendroglial tumors (10 low-grade and 4 anaplastic oligodendroglioma) to evaluate the frequency of LOH on 1p, 10q and 19q and correlate it with tumor grade and patients' age and gender; 5 loci on 1p and 5 on 19q as well as 4 on 10q were analyzed for LOH using PCR techniques. RESULTS: LOH on 1p together with 19q was detected in 6 tumors, 1 tumor showed deletion of 19q accompanied with deletion on 10q. Deletion on 1p was associated with deletion of 19q (p < 0.005) and mutual associations among deletions at loci on 19q (p < 0.05) were found. Patients with LOH on 1p were younger on average than patients with retained heterozygosity (p = 0.05). Grade II oligodendrogliomas predominated among younger patients (p < 0.01) while grade III oligodendrogliomas predominated among women (p < 0.005). No association between LOH on 1p nor 19q and tumor grade or patients' gender was found. CONCLUSION: Our study provides several clinically interesting findings and further supports the hypothesis of chromosome 1p and 19q involvement in the oligodendroglial cancerogenesis.


Subject(s)
Brain Neoplasms/genetics , Brain Neoplasms/pathology , Chromosome Aberrations , DNA, Neoplasm/genetics , Oligodendroglioma/genetics , Adult , Age Factors , Chromosomes, Human, Pair 1/genetics , Chromosomes, Human, Pair 10/genetics , Chromosomes, Human, Pair 19/genetics , Female , Humans , Loss of Heterozygosity , Male , Middle Aged , Oligodendroglioma/pathology , Sex Factors
5.
Cancer Genet Cytogenet ; 162(1): 63-7, 2005 Oct 01.
Article in English | MEDLINE | ID: mdl-16157202

ABSTRACT

Deletions of 1p occur in approximately 30% of meningiomas. Based on loss of heterozygosity (LOH) analysis, two regions on 1p have been suspected to be carriers of tumor suppressor genes. We chose the GADD45A and EPB41 genes as tumor suppressor candidates based on their function and chromosomal localization. We analyzed 19 cases of meningioma with LOH of 1p by means of sequencing of the GADD45A gene and Western blotting of the GADD45a protein. Twenty cases of meningioma without 1p LOH were also analyzed by Western blotting to find out if changes of the GADD45a protein expression occurred. Nineteen samples with 1p LOH (12 grade I; 7 grade II, WHO classification) and 20 samples without 1p LOH (18 grade I; 2 grade II) were also analyzed by means of real-time polymerase chain reaction to find abnormalities in EPB41 mRNA levels in meningioma. LOH analysis was performed using seven microsatellite markers: D1S508 (1p36.2), D1S199 (1p36.1) D1S2734 (1p36.1), D1S2720 (1p34), D1S197 (1p32), D1S162 (1p32), D1S429 (1p11). LOH analysis confirmed previously described localization of putative tumor suppressor genes on 1p and involvement in meningioma pathogenesis (1p36 and 1p32). The open reading frame of GADD45A and intron splicing sites showed neither mutations nor polymorphisms. GADD45a protein molecular weight and expression level were unaltered in meningiomas with and without 1p LOH. We conclude that the GADD45A gene is not involved in meningioma tumorigenesis. EPB41 gene expression was unchanged in all analyzed meningiomas. This suggests that involvement of the EPB41 gene (4.1R protein) in meningioma pathogenesis should be reconsidered.


Subject(s)
Blood Proteins/genetics , Cell Cycle Proteins/genetics , Genes, Tumor Suppressor , Meningeal Neoplasms/genetics , Meningioma/genetics , Microtubule-Associated Proteins/genetics , Nuclear Proteins/genetics , Chromosomes, Human, Pair 1 , Cytoskeletal Proteins , Humans , Loss of Heterozygosity , Membrane Proteins , Polymerase Chain Reaction
6.
Langenbecks Arch Surg ; 390(3): 209-15, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15645281

ABSTRACT

BACKGROUND: The range of lymphadenectomy in differentiated thyroid cancer remains still a matter of controversy because of the lack of reliable diagnostic methods for nodal metastases, other than histopathology. AIM: To compare the results of detection of lymph node metastases of papillary thyroid cancer by conventional histopathology and immunohistochemistry with the results of reverse transcription-polymerase chain reaction for thyroglobulin mRNA. PATIENTS AND METHODS: Each of 166 cervical lymph nodes obtained from 21 patients was divided into two halves: one was used for conventional histopathology and immunohistochemistry, the other part was investigated by molecular examination. RESULTS: We obtained different results from examination of the lymph nodes in six (28.6%) patients. In four patients (19.1%) reverse transcription-polymerase chain reaction (RT-PCR) was more sensitive in detection of positive lymph nodes; in two patients (9.5%) it revealed fewer metastasised lymph nodes than did histopathology. The rest of the patients did not have any differences: 12 (57.1%) of them had negative lymph nodes and three (14.3%) had positive lymph nodes in all examinations. CONCLUSIONS: (1) Thyroglobulin (Tg) RT-PCR is an appropriate method of detection for thyroid cancer cells. (2) In combination with histopathology, it might help to qualify patients' nodal status better.


Subject(s)
Adenocarcinoma, Papillary/pathology , Lymphatic Metastasis/diagnosis , Thyroid Neoplasms/pathology , Adenocarcinoma, Papillary/surgery , Adult , Female , Humans , Immunohistochemistry , Lymph Node Excision , Male , Middle Aged , Reverse Transcriptase Polymerase Chain Reaction , Thyroglobulin/metabolism , Thyroid Neoplasms/surgery
7.
Mol Pathol ; 56(5): 299-301, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14514925

ABSTRACT

BACKGROUND: INI1 (hSNF5) mutations are linked to rhabdoid tumours, but mutations in meningiomas with hot spot mutations in position 377 have also been reported. AIMS: To analyse the INI1 gene in meningioma. METHODS: Exons 1, 4, 5, and 9 of the INI1 gene were analysed by the polymerase chain reaction and direct sequencing in 80 meningiomas. For all cases, western blotting of the INI1 protein was performed. RESULTS: Only one of the 80 samples showed a cytosine insertion in codon 376. This mutation changed the open reading frame in almost the whole exon 9 and resulted in a longer hSNF5 protein. Complex analysis of the above described tumour sample by western blotting, DNA sequencing, and loss of heterozygosity (LOH) analysis showed that this particular meningioma consisted of heterogeneic cellular components. One of these components had a mutated INI1 gene, whereas in the other component INI1 was intact. CONCLUSIONS: INI1 mutation is a rare event in the molecular pathology of meningiomas. It is possible for the INI1 gene to be mutated in only a proportion of meningioma cells.


Subject(s)
DNA-Binding Proteins/genetics , Meningioma/genetics , Mutation , Neoplasm Proteins/genetics , Amino Acid Sequence , Base Sequence , Blotting, Western/methods , Chromosomal Proteins, Non-Histone , Humans , Loss of Heterozygosity , Molecular Sequence Data , Polymerase Chain Reaction/methods , SMARCB1 Protein , Transcription Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...